TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 45nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 75nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 86nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 110nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 160nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 180nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 200nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 270nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 650nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 830nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
Affinity DataKi: 1.60E+3nMAssay Description:Binding affinity against 5-hydroxytryptamine 7 receptorMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2.05E+3nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
Affinity DataKi: 3.20E+3nMAssay Description:Binding affinity against dopamine D2 receptorMore data for this Ligand-Target Pair
Affinity DataKi: 4.20E+3nMAssay Description:Binding affinity against Neuropeptide Y receptor type 1 using [125I]-PYYMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity against 5-hydroxytryptamine 6 receptorMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals
Curated by ChEMBL
Agouron Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: >1.00E+5nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 beta (30% inhibition at 100 uM)More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.480nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.686nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.731nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.75nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.788nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.989nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.01nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.03nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.10nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.43nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.44nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.57nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.58nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.59nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.70nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.77nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 1.80nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair